Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity

Shih Lung Woo, Hang Xu, Honggui Li, Yan Zhao, Xiang Hu, Jiajia Zhao, Xin Guo, Ting Guo, Rachel Botchlett, Ting Qi, Ya Pei, Juan Zheng, Yiming Xu, Xiaofei An, Lulu Chen, Lili Chen, Qifu Li, Xiaoqiu Xiao, Yuqing Huo, Chaodong Wu

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is closely associated with obesity and insulin resistance. To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity. C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity-associated NAFLD and treated with metformin (150 mg/kg/d) orally for the last four weeks of HFD feeding. Compared with HFD-fed control mice, metformin-treated mice showed improvement in both glucose tolerance and insulin sensitivity. Also, metformin treatment caused a significant decrease in liver weight, but not adiposity. As indicated by histological changes, metformin treatment decreased hepatic steatosis, but not the size of adipocytes. In addition, metformin treatment caused an increase in the phosphorylation of liver AMP-activated protein kinase (AMPK), which was accompanied by an increase in the phosphorylation of liver acetyl-CoA carboxylase and decreases in the phosphorylation of liver c-Jun N-terminal kinase 1 (JNK1) and in the mRNA levels of lipogenic enzymes and proinflammatory cytokines. However, metformin treatment did not significantly alter adipose tissue AMPK phosphorylation and inflammatory responses. In cultured hepatocytes, metformin treatment increased AMPK phosphorylation and decreased fat deposition and inflammatory responses. Additionally, in bone marrow-derived macrophages, metformin treatment partially blunted the effects of lipopolysaccharide on inducing the phosphorylation of JNK1 and nuclear factor kappa B (NF-kB) p65 and on increasing the mRNA levels of proinflammatory cytokines. Taken together, these results suggest that metformin protects against obesity-associated NAFLD largely through direct effects on decreasing hepatocyte fat deposition and on inhibiting inflammatory responses in both hepatocytes and macrophages. Copyright:

Original languageEnglish (US)
Article numbere91111
JournalPloS one
Volume9
Issue number3
DOIs
StatePublished - Mar 17 2014

Fingerprint

metformin
Metformin
fatty liver
Nutrition
Liver
obesity
Obesity
inflammation
Phosphorylation
Diet
Inflammation
Phenotype
phenotype
phosphorylation
diet
AMP-activated protein kinase
Fats
AMP-Activated Protein Kinases
High Fat Diet
high fat diet

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. / Woo, Shih Lung; Xu, Hang; Li, Honggui; Zhao, Yan; Hu, Xiang; Zhao, Jiajia; Guo, Xin; Guo, Ting; Botchlett, Rachel; Qi, Ting; Pei, Ya; Zheng, Juan; Xu, Yiming; An, Xiaofei; Chen, Lulu; Chen, Lili; Li, Qifu; Xiao, Xiaoqiu; Huo, Yuqing; Wu, Chaodong.

In: PloS one, Vol. 9, No. 3, e91111, 17.03.2014.

Research output: Contribution to journalArticle

Woo, SL, Xu, H, Li, H, Zhao, Y, Hu, X, Zhao, J, Guo, X, Guo, T, Botchlett, R, Qi, T, Pei, Y, Zheng, J, Xu, Y, An, X, Chen, L, Chen, L, Li, Q, Xiao, X, Huo, Y & Wu, C 2014, 'Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity', PloS one, vol. 9, no. 3, e91111. https://doi.org/10.1371/journal.pone.0091111
Woo, Shih Lung ; Xu, Hang ; Li, Honggui ; Zhao, Yan ; Hu, Xiang ; Zhao, Jiajia ; Guo, Xin ; Guo, Ting ; Botchlett, Rachel ; Qi, Ting ; Pei, Ya ; Zheng, Juan ; Xu, Yiming ; An, Xiaofei ; Chen, Lulu ; Chen, Lili ; Li, Qifu ; Xiao, Xiaoqiu ; Huo, Yuqing ; Wu, Chaodong. / Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. In: PloS one. 2014 ; Vol. 9, No. 3.
@article{7444dddaee4b492bb52d0be6bb8c8c76,
title = "Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is closely associated with obesity and insulin resistance. To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity. C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity-associated NAFLD and treated with metformin (150 mg/kg/d) orally for the last four weeks of HFD feeding. Compared with HFD-fed control mice, metformin-treated mice showed improvement in both glucose tolerance and insulin sensitivity. Also, metformin treatment caused a significant decrease in liver weight, but not adiposity. As indicated by histological changes, metformin treatment decreased hepatic steatosis, but not the size of adipocytes. In addition, metformin treatment caused an increase in the phosphorylation of liver AMP-activated protein kinase (AMPK), which was accompanied by an increase in the phosphorylation of liver acetyl-CoA carboxylase and decreases in the phosphorylation of liver c-Jun N-terminal kinase 1 (JNK1) and in the mRNA levels of lipogenic enzymes and proinflammatory cytokines. However, metformin treatment did not significantly alter adipose tissue AMPK phosphorylation and inflammatory responses. In cultured hepatocytes, metformin treatment increased AMPK phosphorylation and decreased fat deposition and inflammatory responses. Additionally, in bone marrow-derived macrophages, metformin treatment partially blunted the effects of lipopolysaccharide on inducing the phosphorylation of JNK1 and nuclear factor kappa B (NF-kB) p65 and on increasing the mRNA levels of proinflammatory cytokines. Taken together, these results suggest that metformin protects against obesity-associated NAFLD largely through direct effects on decreasing hepatocyte fat deposition and on inhibiting inflammatory responses in both hepatocytes and macrophages. Copyright:",
author = "Woo, {Shih Lung} and Hang Xu and Honggui Li and Yan Zhao and Xiang Hu and Jiajia Zhao and Xin Guo and Ting Guo and Rachel Botchlett and Ting Qi and Ya Pei and Juan Zheng and Yiming Xu and Xiaofei An and Lulu Chen and Lili Chen and Qifu Li and Xiaoqiu Xiao and Yuqing Huo and Chaodong Wu",
year = "2014",
month = "3",
day = "17",
doi = "10.1371/journal.pone.0091111",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity

AU - Woo, Shih Lung

AU - Xu, Hang

AU - Li, Honggui

AU - Zhao, Yan

AU - Hu, Xiang

AU - Zhao, Jiajia

AU - Guo, Xin

AU - Guo, Ting

AU - Botchlett, Rachel

AU - Qi, Ting

AU - Pei, Ya

AU - Zheng, Juan

AU - Xu, Yiming

AU - An, Xiaofei

AU - Chen, Lulu

AU - Chen, Lili

AU - Li, Qifu

AU - Xiao, Xiaoqiu

AU - Huo, Yuqing

AU - Wu, Chaodong

PY - 2014/3/17

Y1 - 2014/3/17

N2 - Non-alcoholic fatty liver disease (NAFLD) is closely associated with obesity and insulin resistance. To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity. C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity-associated NAFLD and treated with metformin (150 mg/kg/d) orally for the last four weeks of HFD feeding. Compared with HFD-fed control mice, metformin-treated mice showed improvement in both glucose tolerance and insulin sensitivity. Also, metformin treatment caused a significant decrease in liver weight, but not adiposity. As indicated by histological changes, metformin treatment decreased hepatic steatosis, but not the size of adipocytes. In addition, metformin treatment caused an increase in the phosphorylation of liver AMP-activated protein kinase (AMPK), which was accompanied by an increase in the phosphorylation of liver acetyl-CoA carboxylase and decreases in the phosphorylation of liver c-Jun N-terminal kinase 1 (JNK1) and in the mRNA levels of lipogenic enzymes and proinflammatory cytokines. However, metformin treatment did not significantly alter adipose tissue AMPK phosphorylation and inflammatory responses. In cultured hepatocytes, metformin treatment increased AMPK phosphorylation and decreased fat deposition and inflammatory responses. Additionally, in bone marrow-derived macrophages, metformin treatment partially blunted the effects of lipopolysaccharide on inducing the phosphorylation of JNK1 and nuclear factor kappa B (NF-kB) p65 and on increasing the mRNA levels of proinflammatory cytokines. Taken together, these results suggest that metformin protects against obesity-associated NAFLD largely through direct effects on decreasing hepatocyte fat deposition and on inhibiting inflammatory responses in both hepatocytes and macrophages. Copyright:

AB - Non-alcoholic fatty liver disease (NAFLD) is closely associated with obesity and insulin resistance. To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity. C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity-associated NAFLD and treated with metformin (150 mg/kg/d) orally for the last four weeks of HFD feeding. Compared with HFD-fed control mice, metformin-treated mice showed improvement in both glucose tolerance and insulin sensitivity. Also, metformin treatment caused a significant decrease in liver weight, but not adiposity. As indicated by histological changes, metformin treatment decreased hepatic steatosis, but not the size of adipocytes. In addition, metformin treatment caused an increase in the phosphorylation of liver AMP-activated protein kinase (AMPK), which was accompanied by an increase in the phosphorylation of liver acetyl-CoA carboxylase and decreases in the phosphorylation of liver c-Jun N-terminal kinase 1 (JNK1) and in the mRNA levels of lipogenic enzymes and proinflammatory cytokines. However, metformin treatment did not significantly alter adipose tissue AMPK phosphorylation and inflammatory responses. In cultured hepatocytes, metformin treatment increased AMPK phosphorylation and decreased fat deposition and inflammatory responses. Additionally, in bone marrow-derived macrophages, metformin treatment partially blunted the effects of lipopolysaccharide on inducing the phosphorylation of JNK1 and nuclear factor kappa B (NF-kB) p65 and on increasing the mRNA levels of proinflammatory cytokines. Taken together, these results suggest that metformin protects against obesity-associated NAFLD largely through direct effects on decreasing hepatocyte fat deposition and on inhibiting inflammatory responses in both hepatocytes and macrophages. Copyright:

UR - http://www.scopus.com/inward/record.url?scp=84898619692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898619692&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0091111

DO - 10.1371/journal.pone.0091111

M3 - Article

C2 - 24638078

AN - SCOPUS:84898619692

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e91111

ER -